Streetbeat News

PODD

Insulet Corporation

https://www.insulet.com

Industry

Medical - Devices

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Open

256.90

Mkt cap

19B

Volume

1.5M

High

275.52

P/E Ratio

45.58

52-wk high

275.52

Low

254.44

Div yield

N/A

52-wk low

152.04

Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on Insulet (NASDAQ:PODD) and raised the price target from $230 to $285.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:50 am

Insider sales were reported for Upstart Holdings, Zillow Group, Intuit, and Insulet. These sales may indicate concerns about company prospects or stock overvaluation. Notable sales include Upstart's CFO selling 1,500 shares, Zillow's President selling 6,031 shares, Intuit's CTO selling 2,941 shares, and Insulet's Director selling 5,000 shares.

Portfolio Pulse from Avi Kapoor

September 12, 2024 | 11:44 am

Insulet (NASDAQ:PODD) has significantly outperformed the market over the past 15 years, with an average annual return of 22.2%. A $1000 investment in Insulet 15 years ago would now be worth $20,354.17. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 4:00 pm

Affirm, Mongodb, and Best Buy were among the top large-cap gainers last week, driven by strong earnings and positive guidance. Other notable gainers included Nutanix, GE Vernova, and Trip.com, with several companies receiving analyst upgrades.

Portfolio Pulse from Lekha Gupta

September 02, 2024 | 1:31 pm

Insulet's short interest has decreased by 8.83%, with 2.71 million shares sold short, representing 5.16% of its float. This is higher than its peers' average of 4.39%. The decrease in short interest may indicate a more bullish sentiment.

Portfolio Pulse from Benzinga Insights

August 30, 2024 | 5:00 pm

Insulet's shares have risen following the announcement that its Omnipod device is now approved for use by people with type 2 diabetes in the US.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 5:59 pm

Insulet (NASDAQ:PODD) has significantly outperformed the market over the past decade, with an average annual return of 18.7%. A $1000 investment in PODD 10 years ago would now be worth $5,552.50. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

August 28, 2024 | 3:00 pm

Insulet's shares are rising following the announcement that its Omnipod device is now approved for use by individuals with type 2 diabetes in the US.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 3:04 pm

Insulet's Omnipod 5 has become the first FDA-cleared automated insulin delivery system for both Type 1 and Type 2 diabetes. It features SmartAdjust technology to enhance health outcomes and simplify diabetes management.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 8:21 pm

The S&P 500 and Nasdaq 100 indices ended their 8-day winning streak due to a lack of economic data and hawkish comments from Fed Governor Michelle Bowman. Major drags included Nvidia, Exxon Mobil, and energy stocks, while some sectors like consumer staples and healthcare saw gains.

Portfolio Pulse from Piero Cingari

August 20, 2024 | 8:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.